New Application for Bayer Heart Drug
Bayer’s cooperation partner, Janssen Research & Development, L.L.C. has submitted a Supplemental New Drug Application ( sNDA ) to the U.S. Food and Drug Administration (FDA) for the oral anticoagulant Xarelto ( rivaroxaban ) in combination with standard antiplatelet therapy to reduce the risk of (thrombotic) cardiovascular events in patients with Acute Coronary Syndrome (ACS).